ADIM
RGEN icon

Alpha DNA Investment Management’s Repligen RGEN Stock Holding History

Alpha DNA Investment Management’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,779
Closed -$540K – 528
2021
Q1 		$540K Buy
2,779
+2,130
+328% +$437K 0.62% 89
2020
Q4 		$124K Buy
+649
New +$118K 0.13% 126

Other funds holding RGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Alpha DNA Investment Management's RGEN Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Repligen (RGEN) in Q2 2021, closing a stake of 2,779 shares — an estimated $540K sold.

Alpha DNA Investment Management first reported a position in RGEN in Q4 2020 and held it in 2 quarters. The position peaked at $540K in Q1 2021. 428 funds tracked by Wall St. Rank hold RGEN as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Repligen position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 2,779 Repligen shares in Q2 2021, an estimated $540K.
  • Alpha DNA Investment Management first reported a position in Repligen in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Repligen position peaked at $540K in Q1 2021.
  • 428 funds tracked by Wall St. Rank held Repligen as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.